Is parking available at the Southwest Sacramento clinic
Jul 1, 2026 BPC-157 Before the FDA: Briefing Document Focuses on Ulcerative Colitis BPC-157 will be evaluated by the FDA's Pharmacy Compounding Advisory Committee on July 23, 2026
Dose NAD+ precursors in the morning alongside 5-Amino-1MQ to align with circadian synthesis peaks
Helps calm inflammation associated with tendonitis, digestive disorders, and inflammatory conditions
FDA currently lists BPC-157 among compounding substances for which it has identified potential immunogenicity, peptide-impurity, and API-characterization concerns, while noting that it has limited safety information for proposed routes of administration
Inflammatory cell numbers decreased more rapidly in BPC-157-treated burns compared to controls or silver sulfadiazine-treated wounds